Navigation Links
BioMedical Enterprises, Inc. (BME) Introduces the HammerLock™ Shape Memory Device for Hammertoes.
Date:10/18/2010

SAN ANTONIO, Oct. 18 /PRNewswire/ -- BioMedical Enterprises, Inc. (BME), a privately held medical device company and leader in orthopedic shape memory implant technology, announces the nationwide launch of the HammerLock™ Intramedullary Nitinol Fixation System for use in the correction of hammertoes.  

A hammertoe is a permanent and sometimes painful deformity of the proximal joint of the 2nd through 5th toes.  Hundreds of thousands of people seek treatment each year for this condition and surgical intervention is often necessary to bring relief to the patient.  The most common correction method involves the use of a thin wire to stabilize the joint.  This method, which leaves the wire exposed for several weeks, results in complications and is an inconvenience for the patient.  

The BME HammerLock™ stabilizes the proximal joint of the toe without the need for exposed wires. Formed out of the biocompatible shape memory alloy Nitinol, the HammerLock™ is designed to change shape when exposed to body heat.  After being placed internally across the joint in its closed, spear-like shape, the implant morphs as it warms to normal limb temperature to provide strong fixation of the proximal joint of the toe.  Its spring-like behavior then compresses the joint long-term resulting in an optimal environment for healing.  

Made by Texas-based BME, the only Nitinol small bone fixation manufacturer in the U.S., the HammerLock™ was carefully designed with the feedback of dozens of foot surgeons from across the country resulting in an advanced, robust implant that provides secure fixation.  In addition, the implant's patent-pending storage and deployment system sets a new standard for quick, simple and precise insertion minimizing operating room time.  

"The new BME HammerLock™ intramedullary implant has improved my patient outcomes for hammertoe surgery," says Dr. Jeremy McVay.  "It is easy to implant and comes in a variety of sizes to better suit each patient.  The superior design provides better compressive capabilities compared to others on the market."

Mr. Keith M Peeples, President and CEO of BME stated, "Patients and surgeons have asked for another new intramedullary device for the treatment of hammertoes and the BME HammerLock™ has proven to be an excellent next step.  This is the first of many new products being delivered from the BME drawing board."

BioMedical Enterprises, Inc., (BME) originally founded as a biomedical research firm specializing in bone healing, is now a reconstructive bone fusion product company and the worldwide leader in the understanding of memory metal and its orthopedic applications.  BME was the first company to introduce above body temperature shape changing memory metal staples to the U.S., the first to develop and patent a method of controlling their compressive forces and the only U.S.-based memory metal small bone implant manufacturer.  For more information, visit www.bmeortho.com.


'/>"/>
SOURCE BioMedical Enterprises, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston University Biomedical Engineers Find Chink in Bacterias Armor
2. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
3. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
4. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
5. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
6. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
7. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
8. Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medicals Subsidiary, Sanvita, Inc.
9. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
10. Volcano Corporation Completes Acquisition of Lumen Biomedicals Xtract(TM) Thrombus Aspiration Catheter
11. Biomedical Advanced Research and Development Authority (BARDA) Project for Radiation Exposure Research Awarded to SRI International
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):